Related Experiment Videos
Antigen-Specific Immunotherapy with Thyrotropin Receptor Peptides in Graves' Hyperthyroidism: A Phase I Study
Simon H S Pearce1, Colin Dayan2, David C Wraith3,4,5
11Institute for Genetic Medicine, Newcastle University, and Newcastle Hospitals NHS Trust, Newcastle upon Tyne, United Kingdom.
Summary
This study tested a new Graves' disease treatment, ATX-GD-59, using thyrotropin receptor (TSHR) peptides. The therapy showed promise, with 70% of participants experiencing improved thyroid hormone levels and good tolerability.
Area of Science:
- Endocrinology
- Immunology
- Clinical Trials
Background:
- Graves' disease is a common autoimmune disorder with suboptimal treatments.
- Thyrotropin receptor (TSHR) peptides are explored for antigen-specific immunotherapy.
Purpose of the Study:
- To evaluate the safety and tolerability of ATX-GD-59 in a first-in-human trial.
- To assess the preliminary efficacy of ATX-GD-59 in patients with Graves' hyperthyroidism.
Main Methods:
- Phase I, open-label trial involving 12 participants with mild to moderate Graves' hyperthyroidism.
- Administration of 10 intradermal doses of ATX-GD-59 over 18 weeks.
- Monitoring of adverse events, tolerability, thyroid hormones, and TSHR autoantibodies.
Main Results:
- 70% of participants (7/10) showed improved free thyroid hormones by study completion.
- A significant reduction in serum TSHR autoantibody concentrations was observed.
- Mild injection-site reactions were the most frequent adverse events, indicating good tolerability.
Conclusions:
- ATX-GD-59 demonstrates safety and tolerability in a Phase I trial for Graves' hyperthyroidism.
- Preliminary efficacy suggested by improved thyroid hormone levels in a majority of participants.
- ATX-GD-59 represents a potential novel therapeutic approach for Graves' disease.